NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

LearningCurve, I want to qualify my previous response. DCVax-l should/would target EGFRviii if it is present in the tumor cell.

However, car-t that target egfr wildtype are targeting normal cells with normal antigens, so I don’t believe DCVax-l would target them. They are important for normal cell function throughout the body.

Car-t isn’t necessary to target the former EGFRviii, (see first paragraph), imo. There are many less expensive ways.

Since the results of only targeting these two antigens provides very temporary results, the experimental therapy is useless as a monotherapy. Imo. Moreover, added chemo will reduce immune system response, and will not tackle the issue of tumor escape.